10x Genomics reports preliminary Q4 revenue of $184M, up 18% YoY; instruments up 72%

10x Genomics, Inc.

2023-FY EPS reported -$2.18 revenue$618,727,000

Preliminary Q4 2023 revenue ~$184.0M, 18% growth over prior year; full-year revenue ~$618.7M, up 20%.
Q4 instruments revenue ~$38.4M (+72% YoY), driven by Spatial ($27.2M) and Chromium ($11.1M).
Q4 consumables revenue ~$140.3M (+7% YoY); services revenue ~$5.3M (+129% YoY).
Cumulative instruments sold exceeded 5,900 as of year-end 2023, including over 5,150 Chromium, 500 Visium, 250 Xenium.
Final audited results expected in February 2024 earnings call; preliminary figures subject to adjustment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

10x Genomics, Inc. reported the three months ended December 31, 2023 results: revenue $184.0 million.

Period: the three months ended December 31, 2023
Revenue: $184.0 million
Result: preliminary results

Exact text from the filing

Revenue of approximately $184.0 million for the three months ended December 31, 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

10x Genomics, Inc. reported the year ended December 31, 2023 results: revenue $618.7 million.

Period: the year ended December 31, 2023
Revenue: $618.7 million
Result: preliminary results

Exact text from the filing

Revenue of approximately $618.7 million for the year ended December 31, 2023

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.